Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,19632163,flow rate,"Chromatographic separation was achieved on a Zorbax Extend C(18) column (150mmx4.6mm, i.d., 5microm) using methanol:acetonitrile:5mM ammonium acetate (48:32:20, v/v/v) as the mobile phase at a flow rate of 0.8mL/min.",Determination of arotinoid acid in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19632163/),[ml] / [min],0.8,4216,DB00459,Acitretin
below,2976002,Residual plasma concentrations,Residual plasma concentrations of Ro 13-7652 were below the quantification limit in 7 cases and respectively of 3 and 4 ng/ml in the other 2 cases.,Residual plasma concentrations of acitretin (Ro 10-1670) and its metabolite (Ro 13-7652) after chronic administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2976002/),[ng] / [ml],3,35137,DB00459,Acitretin
,2976002,Residual plasma concentrations,Residual plasma concentrations of Ro 13-7652 were below the quantification limit in 7 cases and respectively of 3 and 4 ng/ml in the other 2 cases.,Residual plasma concentrations of acitretin (Ro 10-1670) and its metabolite (Ro 13-7652) after chronic administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2976002/),[ng] / [ml],4,35138,DB00459,Acitretin
,2575501,systemic clearance,"The systemic clearance of etretinate was significantly lower in the pregnant rats compared to nonpregnant controls (129 vs. 185 ml/hr, respectively; p less than 0.05).",Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. I. Intravenous studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575501/),[ml] / [h],129,47294,DB00459,Acitretin
,2575501,systemic clearance,"The systemic clearance of etretinate was significantly lower in the pregnant rats compared to nonpregnant controls (129 vs. 185 ml/hr, respectively; p less than 0.05).",Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. I. Intravenous studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575501/),[ml] / [h],185,47295,DB00459,Acitretin
,2575501,formation clearance,This decrease was entirely due to a lower formation clearance of acitretin (acid) from etretinate (ester) in the pregnant animals (96 vs. 146 ml/hr; p less than 0.05).,Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. I. Intravenous studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575501/),[ml] / [h],96,47296,DB00459,Acitretin
,2575501,formation clearance,This decrease was entirely due to a lower formation clearance of acitretin (acid) from etretinate (ester) in the pregnant animals (96 vs. 146 ml/hr; p less than 0.05).,Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. I. Intravenous studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575501/),[ml] / [h],146,47297,DB00459,Acitretin
,2575501,systemic clearance,"By contrast, the systemic clearance of acitretin was greater in the pregnant compared to the nonpregnant control animals (184 vs. 145 ml/hr, respectively; p less than 0.05).",Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. I. Intravenous studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575501/),[ml] / [h],184,47298,DB00459,Acitretin
,2575501,systemic clearance,"By contrast, the systemic clearance of acitretin was greater in the pregnant compared to the nonpregnant control animals (184 vs. 145 ml/hr, respectively; p less than 0.05).",Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. I. Intravenous studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575501/),[ml] / [h],145,47299,DB00459,Acitretin
,2575501,systemic clearances,Etretinate infusions in nonpregnant animals yielded systemic clearances (mean = 164 ml/hr) which were similar to those obtained for bolus dose experiments.,Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. I. Intravenous studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575501/),[ml] / [h],164,47300,DB00459,Acitretin
,8149886,Tissue/plasma concentration ratios,"Tissue/plasma concentration ratios ranged from 14 to 1, with the highest value in adipose tissue.",Kinetics of tissue distribution and elimination of retinoid drugs in the rat. II. Etretinate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149886/),,14 to 1,49436,DB00459,Acitretin
,8149886,terminal half-lives,"Etretinate elimination, in most tissues, was biphasic with terminal half-lives of 41 hr in skin, 1-6 hr in other lean tissues, and 1.7 hr in plasma.",Kinetics of tissue distribution and elimination of retinoid drugs in the rat. II. Etretinate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149886/),h,41,49437,DB00459,Acitretin
,8149886,terminal half-lives,"Etretinate elimination, in most tissues, was biphasic with terminal half-lives of 41 hr in skin, 1-6 hr in other lean tissues, and 1.7 hr in plasma.",Kinetics of tissue distribution and elimination of retinoid drugs in the rat. II. Etretinate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149886/),h,1-6,49438,DB00459,Acitretin
,8149886,terminal half-lives,"Etretinate elimination, in most tissues, was biphasic with terminal half-lives of 41 hr in skin, 1-6 hr in other lean tissues, and 1.7 hr in plasma.",Kinetics of tissue distribution and elimination of retinoid drugs in the rat. II. Etretinate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149886/),h,1.7,49439,DB00459,Acitretin
,8149886,volume of distribution,"A volume of distribution of 1.7 liters/kg was determined, and a clearance of 12 ml.min-1.kg-1.",Kinetics of tissue distribution and elimination of retinoid drugs in the rat. II. Etretinate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149886/),[l] / [kg],1.7,49440,DB00459,Acitretin
,8149886,clearance,"A volume of distribution of 1.7 liters/kg was determined, and a clearance of 12 ml.min-1.kg-1.",Kinetics of tissue distribution and elimination of retinoid drugs in the rat. II. Etretinate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149886/),[ml] / [kg·min],12,49441,DB00459,Acitretin
,8149885,Tissue/,"Tissue/plasma concentration ratios of acitretin ranged from 2.8 to 0.3 in the order adipose tissue > brain, liver > lung, heart, kidney, spleen > skin, muscle.",Kinetics of tissue distribution and elimination of retinoid drugs in the rat. I. Acitretin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149885/),,2.8 to 0.3,73575,DB00459,Acitretin
,8149885,elimination half-life,"Disappearance was monophasic, with an elimination half-life of 70 min in plasma and 68 +/- 9 min in the nine tissues.",Kinetics of tissue distribution and elimination of retinoid drugs in the rat. I. Acitretin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149885/),min,70,73576,DB00459,Acitretin
,8149885,elimination half-life,"Disappearance was monophasic, with an elimination half-life of 70 min in plasma and 68 +/- 9 min in the nine tissues.",Kinetics of tissue distribution and elimination of retinoid drugs in the rat. I. Acitretin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149885/),min,68,73577,DB00459,Acitretin
,8149885,volume of distribution,The volume of distribution was 0.6 liters/kg and clearance 6 ml.min-1.kg-1.,Kinetics of tissue distribution and elimination of retinoid drugs in the rat. I. Acitretin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149885/),[l] / [kg],0.6,73578,DB00459,Acitretin
,8149885,clearance,The volume of distribution was 0.6 liters/kg and clearance 6 ml.min-1.kg-1.,Kinetics of tissue distribution and elimination of retinoid drugs in the rat. I. Acitretin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149885/),[ml] / [kg·min],6,73579,DB00459,Acitretin
,1352212,half-life,"Etretinate, a highly lipophilic retinoid, is known to accumulate in the human body with a slow systemic elimination (half-life approximately 100 days) after long-term treatment.","Systemic pharmacokinetics of acitretin, etretinate, isotretinoin, and acetylenic retinoids in guinea pigs and obese rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352212/),d,100,83804,DB00459,Acitretin
,2139274,peak plasma concentration levels (Cmax),Group A (n = 8) showed median peak plasma concentration levels (Cmax) 578 ng/ml for E. and 161 ng/ml for A 4h after dosing (tmax).,"[Pharmacokinetics of etretinate, acitretin and 13-cis-acitretin: new results and advantages of blood level oriented clinical use]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139274/),[ng] / [ml],578,92656,DB00459,Acitretin
,2139274,peak plasma concentration levels (Cmax),Group A (n = 8) showed median peak plasma concentration levels (Cmax) 578 ng/ml for E. and 161 ng/ml for A 4h after dosing (tmax).,"[Pharmacokinetics of etretinate, acitretin and 13-cis-acitretin: new results and advantages of blood level oriented clinical use]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139274/),[ng] / [ml],161,92657,DB00459,Acitretin
,2139274,Cmax-levels,The plasma concentration profile of 13-cis A. was plateau-like with Cmax-levels of 138 ng/ml after 4 to 10 hours.,"[Pharmacokinetics of etretinate, acitretin and 13-cis-acitretin: new results and advantages of blood level oriented clinical use]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139274/),[ng] / [ml],138,92658,DB00459,Acitretin
,2139274,Cmax,"In group B treated with 0.3 to 0.4 mg/kg etretinate a trend to increased Cmax-values with 123 ng/ml for E., 44 ng/ml for A. and, more pronounced, 210 ng/ml for 13-cis A. occurred (steady state).","[Pharmacokinetics of etretinate, acitretin and 13-cis-acitretin: new results and advantages of blood level oriented clinical use]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139274/),[ng] / [ml],123,92659,DB00459,Acitretin
,2139274,Cmax,"In group B treated with 0.3 to 0.4 mg/kg etretinate a trend to increased Cmax-values with 123 ng/ml for E., 44 ng/ml for A. and, more pronounced, 210 ng/ml for 13-cis A. occurred (steady state).","[Pharmacokinetics of etretinate, acitretin and 13-cis-acitretin: new results and advantages of blood level oriented clinical use]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139274/),[ng] / [ml],44,92660,DB00459,Acitretin
,2139274,Cmax,"In group B treated with 0.3 to 0.4 mg/kg etretinate a trend to increased Cmax-values with 123 ng/ml for E., 44 ng/ml for A. and, more pronounced, 210 ng/ml for 13-cis A. occurred (steady state).","[Pharmacokinetics of etretinate, acitretin and 13-cis-acitretin: new results and advantages of blood level oriented clinical use]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139274/),[ng] / [ml],210,92661,DB00459,Acitretin
,1535045,area under the insulin-time curve,"The area under the insulin-time curve (baseline corrected) was significantly decreased from 1.20 mU.min.l-1 on Day 1 to 0.89 mU.min.l-1 on Day 10, and was 0.91 mU.min.l-1 on Day 24.",Effect of acitretin on the response to an intravenous glucose tolerance test in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535045/),[min·mu] / [l],1.20,100352,DB00459,Acitretin
,1535045,area under the insulin-time curve,"The area under the insulin-time curve (baseline corrected) was significantly decreased from 1.20 mU.min.l-1 on Day 1 to 0.89 mU.min.l-1 on Day 10, and was 0.91 mU.min.l-1 on Day 24.",Effect of acitretin on the response to an intravenous glucose tolerance test in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535045/),[min·mu] / [l],0.89,100353,DB00459,Acitretin
,1535045,area under the insulin-time curve,"The area under the insulin-time curve (baseline corrected) was significantly decreased from 1.20 mU.min.l-1 on Day 1 to 0.89 mU.min.l-1 on Day 10, and was 0.91 mU.min.l-1 on Day 24.",Effect of acitretin on the response to an intravenous glucose tolerance test in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535045/),[min·mu] / [l],0.91,100354,DB00459,Acitretin
,1535045,insulin sensitivity',The model-derived 'insulin sensitivity' increased from 13.10(-4) l.mU-1.min-1 on Day 1 to 20.10(-4) l.mU-1.min-1 on Day 10 and was 18.10(-4) l.mU-1.min-1 on Day 24.,Effect of acitretin on the response to an intravenous glucose tolerance test in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535045/),[l] / [min·mu],13.10(-4),100355,DB00459,Acitretin
,1535045,insulin sensitivity',The model-derived 'insulin sensitivity' increased from 13.10(-4) l.mU-1.min-1 on Day 1 to 20.10(-4) l.mU-1.min-1 on Day 10 and was 18.10(-4) l.mU-1.min-1 on Day 24.,Effect of acitretin on the response to an intravenous glucose tolerance test in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535045/),[l] / [min·mu],20.10(-4),100356,DB00459,Acitretin
,1535045,insulin sensitivity',The model-derived 'insulin sensitivity' increased from 13.10(-4) l.mU-1.min-1 on Day 1 to 20.10(-4) l.mU-1.min-1 on Day 10 and was 18.10(-4) l.mU-1.min-1 on Day 24.,Effect of acitretin on the response to an intravenous glucose tolerance test in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535045/),[l] / [min·mu],18.10(-4),100357,DB00459,Acitretin
,2141075,systemic clearance (CLs),"The systemic clearance (CLs) of etretinate and the formation clearance (CLf) of the metabolite (acitretin) were lower in the obese rats (132 and 62.4 mL/min, respectively) compared with their lean littermates (197 and 126 mL/min, respectively).",Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in the obese Zucker rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141075/),[ml] / [min],132,102769,DB00459,Acitretin
,2141075,systemic clearance (CLs),"The systemic clearance (CLs) of etretinate and the formation clearance (CLf) of the metabolite (acitretin) were lower in the obese rats (132 and 62.4 mL/min, respectively) compared with their lean littermates (197 and 126 mL/min, respectively).",Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in the obese Zucker rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141075/),[ml] / [min],62.4,102770,DB00459,Acitretin
,2141075,systemic clearance (CLs),"The systemic clearance (CLs) of etretinate and the formation clearance (CLf) of the metabolite (acitretin) were lower in the obese rats (132 and 62.4 mL/min, respectively) compared with their lean littermates (197 and 126 mL/min, respectively).",Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in the obese Zucker rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141075/),[ml] / [min],197,102771,DB00459,Acitretin
,2141075,formation clearance (CLf),"The systemic clearance (CLs) of etretinate and the formation clearance (CLf) of the metabolite (acitretin) were lower in the obese rats (132 and 62.4 mL/min, respectively) compared with their lean littermates (197 and 126 mL/min, respectively).",Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in the obese Zucker rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141075/),[ml] / [min],62.4,102772,DB00459,Acitretin
,2141075,formation clearance (CLf),"The systemic clearance (CLs) of etretinate and the formation clearance (CLf) of the metabolite (acitretin) were lower in the obese rats (132 and 62.4 mL/min, respectively) compared with their lean littermates (197 and 126 mL/min, respectively).",Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in the obese Zucker rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141075/),[ml] / [min],197,102773,DB00459,Acitretin
,2141075,formation clearance (CLf),"The systemic clearance (CLs) of etretinate and the formation clearance (CLf) of the metabolite (acitretin) were lower in the obese rats (132 and 62.4 mL/min, respectively) compared with their lean littermates (197 and 126 mL/min, respectively).",Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in the obese Zucker rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141075/),[ml] / [min],126,102774,DB00459,Acitretin
,2141075,metabolic clearance (CLd),"The remaining metabolic clearance (CLd) was identical for the lean and obese animals (70.9 and 69.9 mL/min, respectively).",Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in the obese Zucker rat. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141075/),[ml] / [min],70.9,102775,DB00459,Acitretin
,2141075,metabolic clearance (CLd),"The remaining metabolic clearance (CLd) was identical for the lean and obese animals (70.9 and 69.9 mL/min, respectively).",Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in the obese Zucker rat. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141075/),[ml] / [min],69.9,102776,DB00459,Acitretin
,2141075,terminal phase half-life (t1/2),The terminal phase half-life (t1/2) was significantly longer in the obese rats (3.52 versus 1.25 h).,Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in the obese Zucker rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141075/),h,3.52,102777,DB00459,Acitretin
,2141075,terminal phase half-life (t1/2),The terminal phase half-life (t1/2) was significantly longer in the obese rats (3.52 versus 1.25 h).,Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in the obese Zucker rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141075/),h,1.25,102778,DB00459,Acitretin
,8013276,terminal elimination half-life,The terminal elimination half-life of total radioactivity from the plasma was approximately 120 hr.,Disposition of [14C]acitretin in humans following oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8013276/),h,120,106722,DB00459,Acitretin
,2977392,AUC0-15,The AUC0-15 for acitretin was increased when administered with food for all subjects (except one) with a mean increase of 90% (from 1175 to 2249 ng/ml.hr).,Food increases the bioavailability of acitretin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2977392/),,224,111565,DB00459,Acitretin
,2977392,maximum plasma concentration of acitretin (Cmax),"The maximum plasma concentration of acitretin (Cmax) was increased by 70% when administered with food (from 245 to 416 ng/ml), while the time to reach Cmax was unaffected.",Food increases the bioavailability of acitretin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2977392/),[ng] / [ml],245,111566,DB00459,Acitretin
,2977392,maximum plasma concentration of acitretin (Cmax),"The maximum plasma concentration of acitretin (Cmax) was increased by 70% when administered with food (from 245 to 416 ng/ml), while the time to reach Cmax was unaffected.",Food increases the bioavailability of acitretin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2977392/),[ng] / [ml],416,111567,DB00459,Acitretin
,2573489,Vdss,The large Vdss (214 +/- 228 liters/kg) of ET and terminal half-life of greater than 300 hr indicated the wide distribution and prolonged storage of ET in the tissues.,The pharmacokinetics of etretinate and its metabolites in the dog. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573489/),[l] / [kg],214,116235,DB00459,Acitretin
greater,2573489,terminal half-life,The large Vdss (214 +/- 228 liters/kg) of ET and terminal half-life of greater than 300 hr indicated the wide distribution and prolonged storage of ET in the tissues.,The pharmacokinetics of etretinate and its metabolites in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573489/),h,300,116236,DB00459,Acitretin
,2573489,oral bioavailability,The oral bioavailability of ET in the dog was 52.5% with 95.4% of the dose available for absorption from the gut lumen.,The pharmacokinetics of etretinate and its metabolites in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573489/),%,52.5,116237,DB00459,Acitretin
,2573489,oral bioavailability,The oral bioavailability of ET in the dog was 52.5% with 95.4% of the dose available for absorption from the gut lumen.,The pharmacokinetics of etretinate and its metabolites in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573489/),%,95,116238,DB00459,Acitretin
,2573489,oral bioavailability,"Although the oral bioavailability of ETA could not be determined because its administration was not possible by the iv route, it appeared that only 16% of an orally administered dose entered the portal circulation from the gut.",The pharmacokinetics of etretinate and its metabolites in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573489/),,16,116239,DB00459,Acitretin
,2573489,oral bioavailability,"The oral bioavailability of c-ETA was 42.4%, but the liver showed little metabolic activity toward c-ETA.(ABSTRACT TRUNCATED AT 250 WORDS)",The pharmacokinetics of etretinate and its metabolites in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573489/),%,42.4,116240,DB00459,Acitretin
,2141193,concentration quotient,"The concentration quotient between embryo and the maternal plasma was between 0.43 and 1.10 for all-trans-etretin, and only 0.16-0.31 for 13-cis-etretin over the time period studied.",Teratogenicity of the 13-cis and all-trans-isomers of the aromatic retinoid etretin: correlation to transplacental pharmacokinetics in mice during organogenesis after a single oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141193/),,0.43 and 1.10,116707,DB00459,Acitretin
,2141193,concentration quotient,"The concentration quotient between embryo and the maternal plasma was between 0.43 and 1.10 for all-trans-etretin, and only 0.16-0.31 for 13-cis-etretin over the time period studied.",Teratogenicity of the 13-cis and all-trans-isomers of the aromatic retinoid etretin: correlation to transplacental pharmacokinetics in mice during organogenesis after a single oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141193/),,0.16-0.31,116708,DB00459,Acitretin
,2575502,steady state trough plasma concentrations,"During a multiple dose regimen of etretinate, steady state trough plasma concentrations of etretinate in nonpregnant female rats reached their peak levels (15 ng/ml) by day 10 and remained between 10 and 15 ng/ml through day 19.",Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. Single and multiple oral dosing studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575502/),[ng] / [ml],15,139926,DB00459,Acitretin
,2575502,steady state trough plasma concentrations,"During a multiple dose regimen of etretinate, steady state trough plasma concentrations of etretinate in nonpregnant female rats reached their peak levels (15 ng/ml) by day 10 and remained between 10 and 15 ng/ml through day 19.",Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. Single and multiple oral dosing studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575502/),[ng] / [ml],10 and 15,139927,DB00459,Acitretin
,2575502,Steady state trough concentrations,Steady state trough concentrations of acitretin in nonpregnant animals following etretinate multiple dosing reached their peak levels (53 ng/ml) at day 7 and declined to 16 ng/ml at day 19.,Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. Single and multiple oral dosing studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575502/),[ng] / [ml],53,139928,DB00459,Acitretin
,2575502,Steady state trough concentrations,Steady state trough concentrations of acitretin in nonpregnant animals following etretinate multiple dosing reached their peak levels (53 ng/ml) at day 7 and declined to 16 ng/ml at day 19.,Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. Single and multiple oral dosing studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575502/),[ng] / [ml],16,139929,DB00459,Acitretin
,2575502,apparent oral bioavailability,"In single dose studies, the apparent oral bioavailability of etretinate was similar (4-5%) for both pregnant and nonpregnant rats (p greater than 0.05).",Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. Single and multiple oral dosing studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575502/),%,4-5,139930,DB00459,Acitretin
,2575502,bioavailability,"Acitretin bioavailability was 10-fold greater than that for etretinate (57%); again, there was no difference between the pregnant and nonpregnant groups (p greater than 0.05).",Influence of pregnancy on the pharmacokinetic disposition of two aromatic retinoids (etretinate and acitretin) in the rat. Single and multiple oral dosing studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575502/),%,57,139931,DB00459,Acitretin
,2147001,terminal half-life,"Because of the long terminal half-life of this drug (100 days), considerable plasma levels of etretinate and its main metabolite, etretin (acitretin), were observed for up to 2 years following discontinuation of therapy.",Teratogenicity of steady-state concentrations of etretinate and metabolite acitretin maintained in maternal plasma and embryo by intragastric infusion during organogenesis in the mouse: a possible model for the extended elimination phase in human therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2147001/),d,100,147806,DB00459,Acitretin
,24445345,flow rate,"The mobile phase was consisted of 40% phase A (MTBE-methanol-acetic acid, 50:50:0.5, v/v) and 60% phase B (water-methanol-acetic acid, 50:50:0.5, v/v) with a flow rate of 0.3 mL/min.",Validation of a liquid chromatography-electrospray ionization-tandem mass spectrometry method for determination of all-trans retinoic acid in human plasma and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24445345/),[ml] / [min],0.3,152682,DB00459,Acitretin
,24445345,m/,"The API 4000 triple quadrupole mass spectrometer was operated in multiple reaction monitoring (MRM) mode via the positive electrospray ionization interface using the transition m/z 301.4→123.1 for ATRA and m/z 326.9→177.1 for IS, respectively.",Validation of a liquid chromatography-electrospray ionization-tandem mass spectrometry method for determination of all-trans retinoic acid in human plasma and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24445345/),,326.9,152683,DB00459,Acitretin
,2959917,lag-time,"In patients receiving etretinate, the lag-time i.e. the time elapsing until appearance of first-order drug absorption was 1.24 +/- 0.27 for the parent drug and 0.69 hrs +/- 0.16 (mean value +/- S.D.) for its metabolite, etretin.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),,1.24,157321,DB00459,Acitretin
,2959917,lag-time,"In patients receiving etretinate, the lag-time i.e. the time elapsing until appearance of first-order drug absorption was 1.24 +/- 0.27 for the parent drug and 0.69 hrs +/- 0.16 (mean value +/- S.D.) for its metabolite, etretin.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),h,0.69,157322,DB00459,Acitretin
,2959917,time elapsing until appearance of first-order drug absorption,"In patients receiving etretinate, the lag-time i.e. the time elapsing until appearance of first-order drug absorption was 1.24 +/- 0.27 for the parent drug and 0.69 hrs +/- 0.16 (mean value +/- S.D.) for its metabolite, etretin.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),,1.24,157323,DB00459,Acitretin
,2959917,time elapsing until appearance of first-order drug absorption,"In patients receiving etretinate, the lag-time i.e. the time elapsing until appearance of first-order drug absorption was 1.24 +/- 0.27 for the parent drug and 0.69 hrs +/- 0.16 (mean value +/- S.D.) for its metabolite, etretin.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),h,0.69,157324,DB00459,Acitretin
,2959917,Absorption half-times,"Absorption half-times were 0.86 +/- 0.04 and 0.55 hrs +/- 0.09, respectively.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),h,0.86,157325,DB00459,Acitretin
,2959917,Absorption half-times,"Absorption half-times were 0.86 +/- 0.04 and 0.55 hrs +/- 0.09, respectively.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),h,0.55,157326,DB00459,Acitretin
,2959917,lag-time,The patients receiving etretin showed a lag-time of 0.42 hrs +/- 0.23 and an absorption half-time of 0.33 hrs +/- 0.28.,Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),h,0.42,157327,DB00459,Acitretin
,2959917,absorption half-time,The patients receiving etretin showed a lag-time of 0.42 hrs +/- 0.23 and an absorption half-time of 0.33 hrs +/- 0.28.,Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),h,0.33,157328,DB00459,Acitretin
,2959917,half-times,"The mean half-times of the distributory phases of disposition for etretinate and etretin were about 1 and 1.3 hrs and the apparent terminal half-lives were 6.57 +/- 2.09 and 5.52 hrs +/- 1.76, respectively.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),h,1,157329,DB00459,Acitretin
,2959917,half-times,"The mean half-times of the distributory phases of disposition for etretinate and etretin were about 1 and 1.3 hrs and the apparent terminal half-lives were 6.57 +/- 2.09 and 5.52 hrs +/- 1.76, respectively.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),h,1.3,157330,DB00459,Acitretin
,2959917,apparent terminal half-lives,"The mean half-times of the distributory phases of disposition for etretinate and etretin were about 1 and 1.3 hrs and the apparent terminal half-lives were 6.57 +/- 2.09 and 5.52 hrs +/- 1.76, respectively.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),h,6.57,157331,DB00459,Acitretin
,2959917,apparent terminal half-lives,"The mean half-times of the distributory phases of disposition for etretinate and etretin were about 1 and 1.3 hrs and the apparent terminal half-lives were 6.57 +/- 2.09 and 5.52 hrs +/- 1.76, respectively.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),h,5.52,157332,DB00459,Acitretin
,2959917,apparent volumes of distributions,"Assuming 40% systemic availability for both drugs the mean apparent volumes of distributions were calculated to be 1.50 +/- 0.46 and 1.31 l X kg-1 +/- 0.53 and mean plasma clearances were 177.8 +/- 105.8 and 175.9 ml X kg-1 X hr-1 +/- 81.4 for etretinate and etretin, respectively.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),[l] / [kg],1.50,157333,DB00459,Acitretin
,2959917,apparent volumes of distributions,"Assuming 40% systemic availability for both drugs the mean apparent volumes of distributions were calculated to be 1.50 +/- 0.46 and 1.31 l X kg-1 +/- 0.53 and mean plasma clearances were 177.8 +/- 105.8 and 175.9 ml X kg-1 X hr-1 +/- 81.4 for etretinate and etretin, respectively.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),[l] / [kg],1.31,157334,DB00459,Acitretin
,2959917,plasma clearances,"Assuming 40% systemic availability for both drugs the mean apparent volumes of distributions were calculated to be 1.50 +/- 0.46 and 1.31 l X kg-1 +/- 0.53 and mean plasma clearances were 177.8 +/- 105.8 and 175.9 ml X kg-1 X hr-1 +/- 81.4 for etretinate and etretin, respectively.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),[ml] / [h·kg],177.8,157335,DB00459,Acitretin
,2959917,plasma clearances,"Assuming 40% systemic availability for both drugs the mean apparent volumes of distributions were calculated to be 1.50 +/- 0.46 and 1.31 l X kg-1 +/- 0.53 and mean plasma clearances were 177.8 +/- 105.8 and 175.9 ml X kg-1 X hr-1 +/- 81.4 for etretinate and etretin, respectively.",Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959917/),[ml] / [h·kg],175.9,157336,DB00459,Acitretin
,8103254,Trough levels,"Trough levels of acitretin in skin were below the quantification limit, increasing to 28 +/- 16 ng/g within 5 h after dosing.","Skin, adipose tissue and plasma levels of acitretin with rare occurrence of esterified acitretin during long-term treatment. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103254/),[ng] / [g],28,176029,DB00459,Acitretin
,8103254,Fat tissue levels,"Fat tissue levels exceeded those of skin, with values of 98 +/- 71 ng/g within 5 h after drug intake.","Skin, adipose tissue and plasma levels of acitretin with rare occurrence of esterified acitretin during long-term treatment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103254/),[ng] / [g],98,176030,DB00459,Acitretin
,2533684,Absorption lag-times,"Absorption lag-times ranged from 0.3-2.5 hr, whereas the apparent absorption first order half-times (t1/2ka) were within the range of 0.3-1.2 hr.",Pharmacokinetics of etretinate in psoriatic patients with liver fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2533684/),h,0.3-2.5,183394,DB00459,Acitretin
,2533684,apparent absorption first order half-times (t1/2ka),"Absorption lag-times ranged from 0.3-2.5 hr, whereas the apparent absorption first order half-times (t1/2ka) were within the range of 0.3-1.2 hr.",Pharmacokinetics of etretinate in psoriatic patients with liver fibrosis. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2533684/),h,0.3-1.2,183395,DB00459,Acitretin
up to,2967472,elimination half-life,"Hitherto, the use of the carboxylic acid ester analogue, etretinate, has been hampered by an extremely long elimination half-life of up to 120 days for this drug.",Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967472/),d,120,191751,DB00459,Acitretin
,2967472,t 1/2 beta,"Etretin as drug was eliminated faster than the metabolite etretin, t 1/2 beta 2.39 +/- 1.16 days compared to 6.51 +/- 2.06 days.",Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967472/),d,2.39,191752,DB00459,Acitretin
,2967472,t 1/2 beta,"Etretin as drug was eliminated faster than the metabolite etretin, t 1/2 beta 2.39 +/- 1.16 days compared to 6.51 +/- 2.06 days.",Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967472/),d,6.51,191753,DB00459,Acitretin
,2967472,t 1/2 lambda,In patients receiving etretinate the terminal disposition or elimination half-lives for cisetretin (t 1/2 lambda 3 15.9 +/- 9.9 days) were longer than for the metabolite etretin and exhibit a pronounced interindividual variation from 4.25 to 22.8 days.,Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967472/),d,15.9,191754,DB00459,Acitretin
,2967472,central compartment of distribution,"Assuming 40% systemic availability for both drugs, the central compartment of distribution constituted about 12-32% in case of etretin and about 0.8-3.6% in case of etretinate of the calculated apparent total volume of distribution at steady state, which showed mean values of 3.5 and 39.6 1.kg.-1, respectively, presumably reflecting the higher lipophilic nature of the latter compound.",Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967472/),%,12-32,191755,DB00459,Acitretin
,2967472,central compartment of distribution,"Assuming 40% systemic availability for both drugs, the central compartment of distribution constituted about 12-32% in case of etretin and about 0.8-3.6% in case of etretinate of the calculated apparent total volume of distribution at steady state, which showed mean values of 3.5 and 39.6 1.kg.-1, respectively, presumably reflecting the higher lipophilic nature of the latter compound.",Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967472/),%,0.8-3.6,191756,DB00459,Acitretin
,2967472,apparent total volume of distribution at steady state,"Assuming 40% systemic availability for both drugs, the central compartment of distribution constituted about 12-32% in case of etretin and about 0.8-3.6% in case of etretinate of the calculated apparent total volume of distribution at steady state, which showed mean values of 3.5 and 39.6 1.kg.-1, respectively, presumably reflecting the higher lipophilic nature of the latter compound.",Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967472/),-1·1·kg,3.5,191757,DB00459,Acitretin
,2967472,apparent total volume of distribution at steady state,"Assuming 40% systemic availability for both drugs, the central compartment of distribution constituted about 12-32% in case of etretin and about 0.8-3.6% in case of etretinate of the calculated apparent total volume of distribution at steady state, which showed mean values of 3.5 and 39.6 1.kg.-1, respectively, presumably reflecting the higher lipophilic nature of the latter compound.",Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967472/),-1·1·kg,39.6,191758,DB00459,Acitretin
up to,1828811,elimination half-life,"Hitherto, the use of the carboxylic acid ester analogue, etretinate, has been hampered by an extremely long elimination half-life of up to 120 days for this drug.",The pharmacokinetics of acitretin and its 13-cis-metabolite in psoriatic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1828811/),d,120,196045,DB00459,Acitretin
,1828811,apparent absorption half-life,The maximum plasma concentration of the drug occurred within about 0.9 to 4.6 hours with an apparent absorption half-life ranging from 0.2 to 1.7 hours and with half-lives of the distribution phase within the range of 1.2 to 3.5 hours.,The pharmacokinetics of acitretin and its 13-cis-metabolite in psoriatic patients. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1828811/),h,0.2 to 1.7,196046,DB00459,Acitretin
,1828811,half-lives of the distribution phase,The maximum plasma concentration of the drug occurred within about 0.9 to 4.6 hours with an apparent absorption half-life ranging from 0.2 to 1.7 hours and with half-lives of the distribution phase within the range of 1.2 to 3.5 hours.,The pharmacokinetics of acitretin and its 13-cis-metabolite in psoriatic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1828811/),h,1.2 to 3.5,196047,DB00459,Acitretin
,1828811,terminal elimination half-life,"After stopping therapy, the terminal elimination half-life of acitretin varied between 16.5 and 111.1 hours (mean: 47.1 hr +/- 29.8 SD), whereas that for the 13-cis-metabolite varied between 36.5 and 249.4 hours (mean: 119.4 hr +/- 73.4 SD).",The pharmacokinetics of acitretin and its 13-cis-metabolite in psoriatic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1828811/),h,16.5 and 111.1,196048,DB00459,Acitretin
,1828811,terminal elimination half-life,"After stopping therapy, the terminal elimination half-life of acitretin varied between 16.5 and 111.1 hours (mean: 47.1 hr +/- 29.8 SD), whereas that for the 13-cis-metabolite varied between 36.5 and 249.4 hours (mean: 119.4 hr +/- 73.4 SD).",The pharmacokinetics of acitretin and its 13-cis-metabolite in psoriatic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1828811/),h,47.1,196049,DB00459,Acitretin
,1828811,terminal elimination half-life,"After stopping therapy, the terminal elimination half-life of acitretin varied between 16.5 and 111.1 hours (mean: 47.1 hr +/- 29.8 SD), whereas that for the 13-cis-metabolite varied between 36.5 and 249.4 hours (mean: 119.4 hr +/- 73.4 SD).",The pharmacokinetics of acitretin and its 13-cis-metabolite in psoriatic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1828811/),h,36.5 and 249.4,196050,DB00459,Acitretin
,1828811,terminal elimination half-life,"After stopping therapy, the terminal elimination half-life of acitretin varied between 16.5 and 111.1 hours (mean: 47.1 hr +/- 29.8 SD), whereas that for the 13-cis-metabolite varied between 36.5 and 249.4 hours (mean: 119.4 hr +/- 73.4 SD).",The pharmacokinetics of acitretin and its 13-cis-metabolite in psoriatic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1828811/),h,119.4,196051,DB00459,Acitretin
,10554045,terminal half-life,"Tazarotenic acid does not accumulate in adipose tissue, but undergoes further metabolism to its sulfoxide and to other polar metabolites and is rapidly eliminated via both urinary and faecal pathways with a terminal half-life of about 18 hours.",Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10554045/),h,18,197411,DB00459,Acitretin
,10554045,systemic bioavailability,"The systemic bioavailability of tazarotene (measured as tazarotenic acid) is low, approximately 1% after single and multiple topical applications to healthy skin.",Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10554045/),%,1,197412,DB00459,Acitretin
,10554045,systemic bioavailability,"In patients with psoriasis under typical conditions of use, systemic bioavailability increased during the initial 2 weeks of treatment from 1% (single dose) to 5% or less (steady state).",Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10554045/),%,1,197413,DB00459,Acitretin
,10554045,systemic bioavailability,"In patients with psoriasis under typical conditions of use, systemic bioavailability increased during the initial 2 weeks of treatment from 1% (single dose) to 5% or less (steady state).",Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10554045/),%,5,197414,DB00459,Acitretin
,2522404,absolute bioavailability,The mean absolute bioavailability of acitretin is 59% with high interpatient variability consistent with that of etretinate.,"Overview of recent clinical pharmacokinetic studies with acitretin (Ro 10-1670, etretin). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2522404/),%,59,218598,DB00459,Acitretin
,2522404,elimination half-life,The drug appears to be extensively distributed throughout the body without unexpected accumulation and the elimination half-life is approximately 50 h.,"Overview of recent clinical pharmacokinetic studies with acitretin (Ro 10-1670, etretin). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2522404/),h,50,218599,DB00459,Acitretin
up,1617858,terminal elimination half-lives,"The terminal elimination half-lives of isotretinoin, etretinate and acitretin after long term treatment are up to 20h, 120 days and 48h, respectively.",Pharmacokinetics and therapeutic efficacy of retinoids in skin diseases. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617858/),h,20,228934,DB00459,Acitretin
,1617858,terminal elimination half-lives,"The terminal elimination half-lives of isotretinoin, etretinate and acitretin after long term treatment are up to 20h, 120 days and 48h, respectively.",Pharmacokinetics and therapeutic efficacy of retinoids in skin diseases. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617858/),d,120,228935,DB00459,Acitretin
,1617858,terminal elimination half-lives,"The terminal elimination half-lives of isotretinoin, etretinate and acitretin after long term treatment are up to 20h, 120 days and 48h, respectively.",Pharmacokinetics and therapeutic efficacy of retinoids in skin diseases. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617858/),h,48,228936,DB00459,Acitretin
,1617858,systemic availability,"Because of lack of definite correlation between plasma concentration and desired pharmacological effects, in conjunction with the very pronounced inter- and intraindividual variation in systemic availability (15 to 90%) after oral administration of these drugs, initial dosages in individual patients can only be roughly judged on the basis of the general pharmacokinetics of the agents.",Pharmacokinetics and therapeutic efficacy of retinoids in skin diseases. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617858/),%,15 to 90,228937,DB00459,Acitretin
,1377120,terminal elimination half-life,"Acitretin is less lipophilic than etretinate, and its lack of sequestration into 'deep' fatty storage sites is reflected in a comparatively short terminal elimination half-life of 50 to 60 hours, compared with 120 days for etretinate.",Acitretin. A review of its pharmacology and therapeutic use. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1377120/),h,50 to 60,238657,DB00459,Acitretin
,1377120,terminal elimination half-life,"Acitretin is less lipophilic than etretinate, and its lack of sequestration into 'deep' fatty storage sites is reflected in a comparatively short terminal elimination half-life of 50 to 60 hours, compared with 120 days for etretinate.",Acitretin. A review of its pharmacology and therapeutic use. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1377120/),d,120,238658,DB00459,Acitretin
,2980988,IC50,"In the in vitro assay, only etretin suppressed chondrogenesis and this activity was equivalent to that of all-trans-retinoic acid (IC50 of 12 ng/ml).",Transplacental pharmacokinetics of teratogenic doses of etretinate and other aromatic retinoids in mice. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2980988/),[ng] / [ml],12,254118,DB00459,Acitretin
,2150173,cis/trans ratio,"When etretinate and acitretin dissolved in ethanol were irradiated with UVB (280-320 nm; 10-336 mJ/cm2) or UVA (320-400 nm; 1-5 J/cm2), extensive and reproducible cis-isomerizations occurred at the 13-position (cis/trans ratio approximately 1.6 in all experiments) but there was no progressive photodegradation of the molecules.",UV-induced isomerization of oral retinoids in vitro and in vivo in hairless mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2150173/),,1.6,257152,DB00459,Acitretin
,19640355,Extraction recovery,Extraction recovery was 75.1 - 91.5%.,A fully validated HPLC method for the simultaneous determination of acitretin and etretinate in plasma and its application to a pharmacokinetic study in healthy Korean subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19640355/),%,75.1 - 91.5,269220,DB00459,Acitretin
,19640355,Cmax,"The mean +/- SD pharmacokinetics of acitretin in Koreans were as follows: Cmax 148.7 +/- 93.0 ng/ml, tmax 3.2 +/- 1.3 h, t1/2 81.2 +/- 26.5 h, and AUClast 2641.9 +/- 1274.8 ng h/ml.",A fully validated HPLC method for the simultaneous determination of acitretin and etretinate in plasma and its application to a pharmacokinetic study in healthy Korean subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19640355/),[ng] / [ml],148.7,269221,DB00459,Acitretin
,19640355,tmax,"The mean +/- SD pharmacokinetics of acitretin in Koreans were as follows: Cmax 148.7 +/- 93.0 ng/ml, tmax 3.2 +/- 1.3 h, t1/2 81.2 +/- 26.5 h, and AUClast 2641.9 +/- 1274.8 ng h/ml.",A fully validated HPLC method for the simultaneous determination of acitretin and etretinate in plasma and its application to a pharmacokinetic study in healthy Korean subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19640355/),h,3.2,269222,DB00459,Acitretin
,19640355,t1/2,"The mean +/- SD pharmacokinetics of acitretin in Koreans were as follows: Cmax 148.7 +/- 93.0 ng/ml, tmax 3.2 +/- 1.3 h, t1/2 81.2 +/- 26.5 h, and AUClast 2641.9 +/- 1274.8 ng h/ml.",A fully validated HPLC method for the simultaneous determination of acitretin and etretinate in plasma and its application to a pharmacokinetic study in healthy Korean subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19640355/),h,81.2,269223,DB00459,Acitretin
,19640355,AUClast,"The mean +/- SD pharmacokinetics of acitretin in Koreans were as follows: Cmax 148.7 +/- 93.0 ng/ml, tmax 3.2 +/- 1.3 h, t1/2 81.2 +/- 26.5 h, and AUClast 2641.9 +/- 1274.8 ng h/ml.",A fully validated HPLC method for the simultaneous determination of acitretin and etretinate in plasma and its application to a pharmacokinetic study in healthy Korean subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19640355/),[h·ng] / [ml],2641.9,269224,DB00459,Acitretin
